NEW YORK, April 30, 2024 /PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for chronic inflammatory and autoimmune diseases, today announced that data from its phase 2 EMPhASIS trial of lead asset, vidofludimus calcium (IMU-838), in patients with relapsing-remitting multiple sclerosis (RRMS) has been published online on April 25, 2024 in Neurology® Neuroimmunology & Neuroinflammation, an official journal of the American Academy of Neurology.
FORT LAUDERDALE, Fla., Aug. 28, 2023 /PRNewswire/ -- Calcium supplements are common. Many Americans fail to achieve the recommended daily dose of calcium through their diets and seek to make up that deficit through a supplement. NIH reports that 32% of women, in particular, take a dietary supplement containing calcium. The National Institute of Health adds that between foods and supplements, the average woman gets around 1009 mg of calcium each day.
DUBLIN, Jan. 3, 2022 /PRNewswire/ -- Jazz Pharmaceuticals, Inc. (Nasdaq: JAZZ) today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Exclusivity (ODE) for Xywav® (calcium, magnesium, potassium, and sodium oxybates) oral solution, for the treatment of idiopathic hypersomnia in adults, making it the second ODE for the medication following the exclusivity granted in the treatment of cataplexy or excessive daytime sleepiness (EDS) in patients 7 years of age and older with narcolepsy.
DUBLIN, Oct. 20, 2020 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced the publication of the global Phase 3 double-blind, placebo-controlled, randomized-withdrawal, multicenter study of Xywav™ (calcium, magnesium, potassium and sodium oxybates) oral solution, for the treatment of cataplexy or excessive daytime sleepiness (EDS) in adults with narcolepsy. The results were published in SLEEP, the peer-reviewed, international journal of the Sleep Research Society.
DEERFIELD, Ill.--(BUSINESS WIRE)--Baxter International Inc. (NYSE: BAX), a global leader in clinical nutrition, today announced the U.S. Food and Drug Administration (FDA) approval of new formulations of Clinimix (amino acids in dextrose) Injections and Clinimix E (amino acids with electrolytes in dextrose and calcium) Injections. These new Clinimix formulations contain up to 80 g/L of amino acids, the highest protein in any multi-chamber bag available in the U.S.,2 making it easier to reach patient protein targets while delivering less fluid and dextrose than provided by existing formulations.3,4
DUBLIN, Aug. 27, 2020 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that 10 abstracts will be presented at Virtual SLEEP 2020, the 34th annual meeting of the Associated Professional Sleep Societies (APSS) from August 28-30. The presentations will debut data across Jazz's neuroscience therapeutic area, featuring important new insights into the company's ongoing sleep medicine research.
Jazz Pharms` Xywav (Calcium;Magnesium:Potassium ) Receives Approval in Europe
DUBLIN, July 22, 2020 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the U.S. Food and Drug Administration (FDA) approved Xywav™ (calcium, magnesium, potassium, and sodium oxybates) oral solution on July 21, 2020 for the treatment of cataplexy or excessive daytime sleepiness (EDS) in patients 7 years of age and older with narcolepsy.1,2 Xywav is an oxybate product with a unique composition of cations resulting in 92 percent less sodium – or approximately 1,000 to 1,500 mg/night – than sodium oxybate at the recommended dosage range of 6 to 9 grams.1
NPPA fixes retail prices of 21 formulations under DPCO 2013
NPPA fixes retail prices of 21 formulations under DPCO 2013